Pneumococcal Community-Acquired Pneumonia Requiring Hospitalization Among Colombian Adults (PneumoCAP)

Pneumococcal Community-Acquired Pneumonia Requiring Hospitalization Among Colombian Adults (Pneumo-CAP Colombia)

Pneumococcal Community-Acquired Pneumonia Requiring Hospitalization Among Adults in Colombia (Pneumo-CAP Colombia)

This study aims to learn more about pneumococcal community-acquired pneumonia (CAP) caused by Streptococcus pneumoniae among adults hospitalized in 11 hospitals in the Sabana Centro region of Colombia. The study will describe the characteristics of adults with CAP, estimate pneumococcal CAP prevalence in the area, and examine the specific serotypes of S. pneumoniae causing this infection. This research is essential for understanding which microorganism is the most prevalent cause of CAP in the region, whether pneumococcal vaccines included in governmental vaccination programs protect adults, which specific pneumococcal serotypes are circulating, and which available vaccine will best protect people against pneumococcal CAP.

The study will be conducted at 11 hospitals in the Sabana Centro region and will collect data over 2 years. The study will gather detailed information on each patient's condition, including symptoms, medical history, and outcomes such as death or the need for intensive care.

Study Overview

• Status: Completed
• Conditions: Pneumococcal Pneumonia; Community Acquired Pneumonia (CAP)

Detailed Description

This prospective, multicenter surveillance study aims to provide a detailed understanding of pneumococcal community-acquired pneumonia (CAP), a leading cause of hospitalization and mortality, in adults in the Sabana Centro region of Colombia. Pneumococcal CAP, caused by the bacterium Streptococcus pneumoniae, remains a significant global health burden despite widespread vaccination programs. The study will investigate the incidence, prevalence, and serotype distribution of pneumococcal CAP, with a particular focus on strains included in the 15-valent pneumococcal conjugate vaccine (PCV15).

The study's objectives will help inform future vaccine development, public health policies, and the clinical management of pneumococcal infections in adult populations, particularly in low- and middle-income countries (LMICs), where vaccine coverage and disease burden remain concerns.

Study Goals and Objectives:

The study has four primary objectives:

1. To describe the demographic and clinical characteristics of adults ≥18 years hospitalized with pneumococcal CAP in the Sabana Centro region, including both bacteremic and non-bacteremic cases of the infection.
2. To determine the prevalence of pneumococcal CAP among patients requiring hospitalization for CAP in the Sabana Centro region of Colombia.
3. To determine the prevalence of pneumococcal serotypes included in the PCV15 vaccine in hospitalized adults with pneumococcal CAP, including both bacteremic and non-bacteremic cases.

4. To estimate the incidence of pneumococcal CAP that requires hospitalization and the contribution of PCV15 serotypes to the disease burden in the region.

   The study will also explore secondary objectives, including the association between pneumococcal positivity and severe clinical outcomes like ICU admission, mechanical ventilation, vasopressor use, and mortality.

   Study Design:

   This is a prospective, observational, multicenter study with active surveillance. The research will take place at 11 hospitals across the Sabana Centro region, including both public and private institutions. The study will collect data over two years, with a recruitment period of one year and a follow-up period of up to three months post-discharge.

   Inclusion and Exclusion Criteria:

   Inclusion Criteria:

   -1. Age ≥ 18 years old.

   -2. Hospitalized at one of the hospitals of Sabana Centro Region, including both in-patient and observation status stay.

   -3.Clinical signs and/or symptoms of an acute respiratory illness, as defined by ≥ 1 of the following:

   -New or worsening shortness of breath in the past 7 days

   -New or worsening cough in the past 7 days

   -New or worsening sputum production in the past 7 days

   -New or worsening chest pain in the past 7 days

   -Tachypnea to respiratory rate ≥ 22 breaths/min, not known to be chronic

   -Hypoxia to SpO2 ≤ 92% not known to be chronic

   -Initiation of invasive or non-invasive mechanical ventilation.

   -4. Clinical signs and/or symptoms of an acute infection, as defined by ≥ 1 of the following:

   -Body temperature ≥ 38º C (100.4º F) or ≤ 35.5º C (95.9º F)

   -Reported fever, chills, or feeling feverish at home without explicit documentation of a fever within the past 7 days

   -White blood cell count > 10.7 or < 3.9 thousand cells/mcL-C-reactive protein > 10 mg/L

   • Altered mental status
   • 5. Radiologic evidence of pneumonia interpreted by a radiologist, defined as ≥ 1 of the following findings on chest x-ray (CXR), computed tomography (CT), or lung ultrasound completed within 48 hours before or after hospital admission:
   • Pulmonary infiltrate not known to be chronic
   • Pulmonary opacity is not known to be chronic (including ground-glass opacities on CT)
   • Pulmonary consolidation is not known to be

   Exclusion Criteria:

   -1. Enrollment in this study within the past 90 days.

   -2. Development of pneumonia (as defined in the inclusion criteria) more than 48 hours after hospital admission (pneumonia developed 48 hours after admission will be considered hospital-acquired pneumonia).

   -3. Inability to obtain consent from patient or surrogate for this study within 48 hours of hospital admission (including time at a transferring hospital before admission at a study hospital).

   -4. Inability or unwillingness of the patient to provide any of the samples (Blood, Urine, and Sputum) within 48 hours of hospital admission (including time at a transferring hospital before admission at a study hospital).

   -5. Non-pneumonia illness completely explains the patient's acute symptoms. Alternative non-pneumonia illnesses could include pulmonary embolism, acute heart failure, lung cancer, and pulmonary hemorrhage.

   o- Key Outcomes and Data Collection:

   The study will track multiple outcomes, including:

   o- Incidence of pneumococcal CAP (overall, and by specific serotypes included in PCV15).

   o- Prevalence of pneumococcal serotypes, particularly those contained in PCV15.

   o- Clinical outcomes such as:

   o Mortality (hospital mortality and 3-month post-discharge mortality)

   o ICU admission

   o Need for invasive mechanical ventilation

   o Use of vasopressors

   o Duration of hospital and ICU stay

   o- Quality of life measures using the EQ-5D-5L and mMRC scales, assessed at baseline, 1 month, and 3 months post-discharge.

   o- Laboratory Tests and Procedures:

   The study will use a combination of diagnostic methods to detect S. pneumoniae and characterize the pneumococcal strains involved, including:

   o Urine antigen tests.

   o Blood cultures.

   • Sputum cultures.
   • Real-time PCR for molecular detection of S. pneumoniae in blood and sputum samples.

   In addition, the study will collect data on the antimicrobial resistance patterns of the isolated pneumococcal strains, evaluating resistance to penicillins, macrolides, and other antibiotic classes.

   o-Data Management and Analysis: All data will be collected electronically through the RedCap platform, a secure, web-based system. The data will be analyzed using descriptive statistics for demographic and clinical characteristics, as well as incidence and prevalence rates of pneumococcal CAP. Multivariate regression models will be used to assess associations between pneumococcal infection and clinical outcomes, while adjusting for potential confounders such as age, sex, comorbidities, and vaccination status.

   o- Follow-Up: Patients will be followed up by phone at 1 and 3 months post-discharge to evaluate long-term outcomes, including survival, functional recovery, and quality of life. This follow-up is crucial for understanding the long-term burden of pneumococcal CAP and the potential impact of vaccination.

   o- Study Timeline and Sample Size: The study is expected to run for 2 years. The study will include all eligible patients hospitalized during this time, and the number of qualifying cases observed will determine the sample size.

   o- Ethical Considerations and Confidentiality: The study will be conducted in accordance with ethical guidelines for human research and will obtain approval from institutional review boards (IRBs) at all participating hospitals. Informed consent will be obtained from all patients (or their legal representatives) before enrollment. All patient data will be kept confidential, and participants will be identified only by a study-specific ID.

   o- Study Significance and Expected Impact: This study is the first of its kind in Colombia to comprehensively evaluate the incidence, prevalence, and clinical outcomes of pneumococcal CAP in adults. The findings will provide crucial data on the pneumococcal serotypes circulating in the region, informing vaccine policy and the potential introduction of new pneumococcal vaccines, such as PCV15, into the Colombian adult population. The study also aims to address the significant knowledge gap in the epidemiology of pneumococcal infections in LMICs, where data on adult pneumococcal CAP is limited.

• Study Type: Observational
• Enrollment (Actual): 688

Contacts and Locations

Study Locations

• Colombia
  • Cajicá, Colombia
    • Centro Medico San Luis Clinica Quirurgica SAS
  • Nemocón, Colombia
    • ESE Hospital San Vicente de Paul Nemocon
  • Sopó, Colombia
    • ESE Hospital divino Salvador Sopo
  • Tabio, Colombia
    • ESE Hospital Nuestra Señora del Carmen de Tabio
  • Tenjo, Colombia
    • ESE Hospital Santa Rosa de Tenjo
  • Tocancipá, Colombia
    • Hospital Nuestra Señora del Transito de Tocancipa
  • Zipaquirá, Colombia
    • Hospital Universitario de la Samaritana Regional
  • Zipaquirá, Colombia
    • Hospital Universitario de la Samaritana sede Funcional
  • Cundinamarca
    • Chía, Cundinamarca, Colombia, 250002
      • Clinica de Marly Jorge Cavelier Gaviria SAS
    • Chía, Cundinamarca, Colombia, 250002
      • Clínica Universidad de La Sabana
    • Chía, Cundinamarca, Colombia, 250002
      • ESE Hospital San Antonio de Chia

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

The study population will consist of adults aged 18 years or older hospitalized with community-acquired pneumonia (CAP) in the Sabana Centro region of Colombia. This region includes 11 municipalities around Bogotá and represents a diverse socio-economic and demographic population with a well-organized healthcare system.

Description

Inclusion Criteria:

• (1) Age ≥ 18 years old.
• (2) Hospitalized at one of the hospitals of Sabana Centro Region, including both in-patient and observation status stay.
• (3) Clinical signs and/or symptoms of an acute respiratory illness, as defined by ≥ 1 of the
• following:
• -New or worsening shortness of breath in the past 7 days
• -New or worsening cough in the past 7 days
• -New or worsening sputum production in the past 7 days
• -New or worsening chest pain in the past 7 days
• -Tachypnea to respiratory rate ≥ 22 breaths/min, not known to be chronic
• -Hypoxia to SpO2 ≤ 92% not known to be chronic
• -Initiation of invasive or non-invasive mechanical ventilation
• (4) Clinical signs and/or symptoms of an acute infection, as defined by ≥ 1 of the following:
• -Body temperature ≥ 38º C (100.4º F) or ≤ 35.5º C (95.9º F)
• -Reported fever, chills, or feeling feverish at home without explicit documentation of a fever within the past 7 days
• -White blood cell count > 10.7 or < 3.9 thousand cells/mcL-C-reactive protein > 10 mg/L
• -Altered mental status
• (5) Radiologic evidence of pneumonia interpreted by a radiologist, defined as ≥ 1 of the following findings on chest x-ray (CXR), computed tomography (CT), or lung ultrasound completed within 48 hours before or after hospital admission:
• -Pulmonary infiltrate not known to be chronic
• -Pulmonary opacity is not known to be chronic (including ground-glass opacities on CT)
• -Pulmonary consolidation is not known to be

Exclusion Criteria:

• (1) Enrollment in this study within the past 90 days.
• (2) Development of pneumonia (as defined in the inclusion criteria) more than 48 hours after hospital admission (pneumonia developed 48 hours after admission will be considered hospital-acquired pneumonia).
• (3) Inability to obtain consent from patient or surrogate for this study within 48 hours of hospital admission (including time at a transferring hospital before admission at a study hospital).
• (4) Inability or unwillingness of the patient to provide any of the samples (Blood, Urine, and Sputum) within 48 hours of hospital admission (including time at a transferring hospital before admission at a study hospital).
• (5) Non-pneumonia illness completely explains the patient's acute symptoms. Alternative non-pneumonia illnesses could include pulmonary embolism, acute heart failure, lung cancer, and pulmonary hemorrhage.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Pneumococcal Community-Acquired Pneumonia (CAP)	This outcome captures how many adults are hospitalized with community-acquired pneumonia caused by Streptococcus pneumoniae, including both bacteremic (positive blood culture) and non-bacteremic cases (positive respiratory sample, urinary antigen test, or PCR). How it will be measured Pneumococcal CAP cases will be identified through routinely collected microbiological results: Blood cultures Respiratory cultures (sputum, BAL, tracheal aspirate) Urinary pneumococcal antigen test PCR/NAAT panels detecting S. pneumoniae All confirmed cases will be counted and divided by the total number of CAP hospitalizations (or by the catchment population, if applicable) to calculate the incidence.	The incidence will be measured throughout the whole study period (from study start to study end), with cases recorded at the time of hospital admission for CAP. (2 years)(Jun-2022 to Nov-2025)
Prevalence of Pneumococcal Serotypes	This outcome describes the frequency with which pneumococcal serotypes covered by the 15-valent conjugate vaccine (PCV15) appear among adults hospitalized with community-acquired pneumonia. How it will be measured All patients with pneumococcal CAP who undergo serotyping will be reviewed. Each serotype identified will be classified as either a PCV15 serotype or a non-PCV15 serotype. The prevalence will be determined by counting the number of pneumococcal CAP cases caused by serotypes included in PCV15, compared with the total number of cases with available serotype information.	Serotypes will be assessed at the time of hospitalization, and the prevalence will be evaluated across the entire study period. (2 years, Jun-2022 until Nov-2025)
Prevalence of Pneumococcal CAP Among Hospitalized Adults	This outcome describes the prevalence of community-acquired pneumococcal pneumonia among adults requiring hospitalization. How it will be measured All hospitalized adults diagnosed with CAP will be reviewed to determine which cases have laboratory confirmation of Streptococcus pneumoniae through blood cultures, respiratory samples, urinary antigen testing, or molecular assays. The prevalence will be determined by counting the number of CAP cases identified as pneumococcal among all CAP hospitalizations.	Pneumococcal CAP cases will be identified at the time of hospital admission, and prevalence will be assessed for the entire study period.(2 years, Jun-2022 until Nov-2025)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Severity of Pneumococcal CAP	This outcome describes the clinical severity of pneumococcal community-acquired pneumonia among hospitalized adults, based on routinely used severity assessment tools. How it will be measured Severity will be determined using any of the three validated clinical scales routinely used by the treating clinician, and patients will be classified as having severe or non-severe disease according to the score applied: Pneumonia Severity Index (PSI) Range: Class I to Class V (0 to >130 points). Higher scores indicate worse severity and higher mortality risk. CURB-65 Score (Confusion, Urea, Respiratory rate, Blood pressure, Age ≥65) Range: 0 to 5 points. Higher scores indicate greater severity and higher mortality risk. Severe Community-Acquired Pneumonia Criteria (American Thoracic Society/Infectious Diseases Society of America) Definition: Severe CAP is identified by 1 major criterion or ≥3 minor criteria. Meeting criteria indicates higher severity and need for intensive care.	Recorded on day 1 ( baseline) and/or at ICU admission when applicable.
Mortality	In-hospital mortality and 3-month post-discharge mortality	from recruitment until 3 months post-discharge
ICU Admission	This outcome captures whether adults hospitalized with CAP require admission to an intensive care unit at any point during their hospitalization, reflecting higher disease severity and need for advanced organ support. How it will be measured ICU admission will be determined through routine hospital records, documenting whether the patient was admitted to an ICU (medical, surgical, or mixed) during the index hospitalization. This includes admissions occurring directly from the emergency department or later during the hospital stay, up to discharge.	Recorded on day of ICU admission (during index hospitalization)
Variation in Quality of Life	This outcome evaluates changes in quality of life among adults hospitalized with CAP, using the standardized EQ-5D-5L instrument, which measures health status across five domains. How it will be measured Quality of life will be assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) scale, which includes five domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each scored from Level 1 (no problems) to Level 5 (extreme problems). The EQ-5D-5L also includes a visual analogue scale (EQ-VAS) ranging from 0 (worst imaginable health) to 100 (best imaginable health). Higher scores on the descriptive system indicate worse health, while higher VAS values indicate better perceived health. Variation will be assessed by comparing scores at different time points, based on when the tool is administered.	Recorded on day 1 ( baseline) and on day 27 after discharge and day 90 after discharge (From recruitment until 3 month post-discharge)
Dyspnea persistence	This outcome evaluates whether adults hospitalized with CAP continue to experience shortness of breath after the acute illness, using a standardized measure of breathlessness severity. How it will be measured Dyspnea will be assessed using the modified Medical Research Council (mMRC) Dyspnea Scale, which ranges from Grade 0 to Grade 4. Grade 0: Breathlessness only with strenuous exercise Grade 1: Shortness of breath when hurrying or walking up a slight hill Grade 2: Walks slower than peers or must stop when walking at own pace Grade 3: Stops for breath after walking ~100 meters Grade 4: Too breathless to leave the house or breathless when dressing Higher mMRC grades indicate worse dyspnea. Persistence will be determined by comparing dyspnea scores across relevant follow-up time points.	Dyspnea will be assessed at the time points defined on Day 1, Day 27 after discharge, and Day 90 after discharge. From baseline until 3 months post-discharge.

Collaborators and Investigators

• Sponsor: Universidad de la Sabana
• Collaborators: Clínica Universidad de La Sabana; Universidad de La Sabana, Colombia
• Investigators: Principal Investigator: Luis F Reyes, MD,PhD, MsC, Universidad de La Sabana; Principal Investigator: Cristian C Serrano, MD, cPhD, Clínica Universidad de La Sabana

Publications and helpful links

General Publications

• van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P, Pickard AS. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012 Jul-Aug;15(5):708-15. doi: 10.1016/j.jval.2012.02.008. Epub 2012 May 24.
• Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.
• American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416. doi: 10.1164/rccm.200405-644ST. No abstract available.
• Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007 Mar 1;44 Suppl 2(Suppl 2):S27-72. doi: 10.1086/511159. No abstract available.
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8.
• Schoenfeld DA, Bernard GR; ARDS Network. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med. 2002 Aug;30(8):1772-7. doi: 10.1097/00003246-200208000-00016.
• Kamdar BB, Huang M, Dinglas VD, Colantuoni E, von Wachter TM, Hopkins RO, Needham DM; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome Network. Joblessness and Lost Earnings after Acute Respiratory Distress Syndrome in a 1-Year National Multicenter Study. Am J Respir Crit Care Med. 2017 Oct 15;196(8):1012-1020. doi: 10.1164/rccm.201611-2327OC.
• Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep. 2008 Apr 24;56(10):1-120.
• Needham DM, Sepulveda KA, Dinglas VD, Chessare CM, Friedman LA, Bingham CO 3rd, Turnbull AE. Core Outcome Measures for Clinical Research in Acute Respiratory Failure Survivors. An International Modified Delphi Consensus Study. Am J Respir Crit Care Med. 2017 Nov 1;196(9):1122-1130. doi: 10.1164/rccm.201702-0372OC.
• Inouye SK, Rushing JT, Foreman MD, Palmer RM, Pompei P. Does delirium contribute to poor hospital outcomes? A three-site epidemiologic study. J Gen Intern Med. 1998 Apr;13(4):234-42. doi: 10.1046/j.1525-1497.1998.00073.x.
• Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, Reed C, Grijalva CG, Anderson EJ, Courtney DM, Chappell JD, Qi C, Hart EM, Carroll F, Trabue C, Donnelly HK, Williams DJ, Zhu Y, Arnold SR, Ampofo K, Waterer GW, Levine M, Lindstrom S, Winchell JM, Katz JM, Erdman D, Schneider E, Hicks LA, McCullers JA, Pavia AT, Edwards KM, Finelli L; CDC EPIC Study Team. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med. 2015 Jul 30;373(5):415-27. doi: 10.1056/NEJMoa1500245. Epub 2015 Jul 14.
• Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997 Jan 23;336(4):243-50. doi: 10.1056/NEJM199701233360402.
• Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, Stockmann C, Anderson EJ, Grijalva CG, Self WH, Zhu Y, Patel A, Hymas W, Chappell JD, Kaufman RA, Kan JH, Dansie D, Lenny N, Hillyard DR, Haynes LM, Levine M, Lindstrom S, Winchell JM, Katz JM, Erdman D, Schneider E, Hicks LA, Wunderink RG, Edwards KM, Pavia AT, McCullers JA, Finelli L; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015 Feb 26;372(9):835-45. doi: 10.1056/NEJMoa1405870.
• Buurman BM, Hoogerduijn JG, de Haan RJ, Abu-Hanna A, Lagaay AM, Verhaar HJ, Schuurmans MJ, Levi M, de Rooij SE. Geriatric conditions in acutely hospitalized older patients: prevalence and one-year survival and functional decline. PLoS One. 2011;6(11):e26951. doi: 10.1371/journal.pone.0026951. Epub 2011 Nov 14.
• Needham DM, Colantuoni E, Mendez-Tellez PA, Dinglas VD, Sevransky JE, Dennison Himmelfarb CR, Desai SV, Shanholtz C, Brower RG, Pronovost PJ. Lung protective mechanical ventilation and two year survival in patients with acute lung injury: prospective cohort study. BMJ. 2012 Apr 5;344:e2124. doi: 10.1136/bmj.e2124.
• Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007 Apr 7;369(9568):1179-86. doi: 10.1016/S0140-6736(07)60564-9.
• Ramirez JA, Wiemken TL, Peyrani P, Arnold FW, Kelley R, Mattingly WA, Nakamatsu R, Pena S, Guinn BE, Furmanek SP, Persaud AK, Raghuram A, Fernandez F, Beavin L, Bosson R, Fernandez-Botran R, Cavallazzi R, Bordon J, Valdivieso C, Schulte J, Carrico RM; University of Louisville Pneumonia Study Group. Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality. Clin Infect Dis. 2017 Nov 13;65(11):1806-1812. doi: 10.1093/cid/cix647.
• Needham DM, Dennison CR, Dowdy DW, Mendez-Tellez PA, Ciesla N, Desai SV, Sevransky J, Shanholtz C, Scharfstein D, Herridge MS, Pronovost PJ. Study protocol: The Improving Care of Acute Lung Injury Patients (ICAP) study. Crit Care. 2006 Feb;10(1):R9. doi: 10.1186/cc3948.
• Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratala J, El Solh AA, Ewig S, Fey PD, File TM Jr, Restrepo MI, Roberts JA, Waterer GW, Cruse P, Knight SL, Brozek JL. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016 Sep 1;63(5):e61-e111. doi: 10.1093/cid/ciw353. Epub 2016 Jul 14.
• Agency for Healthcare Research and Quality. Pneumonia is the Most Common Reason for Hospitalization. http://www.ahrq.gov/research/sep08/0908RA40.htm Accessed: 31 May 2011.
• Self WH, Grijalva CG, Zhu Y, McNaughton CD, Barrett TW, Collins SP, Storrow AB, Griffin MR. Rates of emergency department visits due to pneumonia in the United States, July 2006-June 2009. Acad Emerg Med. 2013 Sep;20(9):957-60. doi: 10.1111/acem.12203. Epub 2013 Aug 27.
• Leal AL, Camacho G, Montañez A, Varon F, Alvarez C, Valderrama S, et al. 1628. Clinical, Epidemiological and Microbiological Characterization of Invasive Streptococcus pneumoniae Disease in Hospitalized Adults from 5 Tertiary Hospitals in Bogotá, Colombia: A Descriptive Study, Open Forum Infectious Diseases, Volume 6, Issue Supplement_2, October 2019, Pages S593-S594.
• Severiche-Bueno DF, Severiche-Bueno DF, Bastidas A, Caceres EL, Silva E, Lozada J, Gomez S, Vargas H, Viasus D, Reyes LF. Burden of invasive pneumococcal disease (IPD) over a 10-year period in Bogota, Colombia. Int J Infect Dis. 2021 Apr;105:32-39. doi: 10.1016/j.ijid.2021.02.031. Epub 2021 Feb 11.
• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, Miller L, Scherzinger K, Thomas A, Farley MM, Zell ER, Taylor TH Jr, Pondo T, Rodgers L, McGee L, Beall B, Jorgensen JH, Whitney CG. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015 Mar;15(3):301-9. doi: 10.1016/S1473-3099(14)71081-3. Epub 2015 Feb 3.
• Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013 Jul 11;369(2):155-63. doi: 10.1056/NEJMoa1209165.
• Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O'Brien KL; AGEDD Adult Pneumococcal Burden Study Team; Andreo F, Beovic B, Blanco S, Boersma WG, Boulware DR, Butler JC, Carratala J, Chang FY, Charles PG, Diaz AA, Dominguez J, Ehara N, Endeman H, Falco V, Falguera M, Fukushima K, Garcia-Vidal C, Genne D, Guchev IA, Gutierrez F, Hernes SS, Hoepelman AI, Hohenthal U, Johansson N, Kolek V, Kozlov RS, Lauderdale TL, Marekovic I, Masia M, Matta MA, Miro O, Murdoch DR, Nuermberger E, Paolini R, Perello R, Snijders D, Plecko V, Sorde R, Stralin K, van der Eerden MM, Vila-Corcoles A, Watt JP. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One. 2013;8(4):e60273. doi: 10.1371/journal.pone.0060273. Epub 2013 Apr 2.
• Wunderink RG, Self WH, Anderson EJ, Balk R, Fakhran S, Courtney DM, Qi C, Williams DJ, Zhu Y, Whitney CG, Moore MR, Bramley A, Jain S, Edwards KM, Grijalva CG. Pneumococcal Community-Acquired Pneumonia Detected by Serotype-Specific Urinary Antigen Detection Assays. Clin Infect Dis. 2018 May 2;66(10):1504-1510. doi: 10.1093/cid/cix1066.
• LeBlanc JJ, ElSherif M, Ye L, MacKinnon-Cameron D, Li L, Ambrose A, Hatchette TF, Lang AL, Gillis H, Martin I, Andrew MK, Boivin G, Bowie W, Green K, Johnstone J, Loeb M, McCarthy A, McGeer A, Moraca S, Semret M, Stiver G, Trottier S, Valiquette L, Webster D, McNeil SA; Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN). Burden of vaccine-preventable pneumococcal disease in hospitalized adults: A Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) network study. Vaccine. 2017 Jun 22;35(29):3647-3654. doi: 10.1016/j.vaccine.2017.05.049. Epub 2017 May 26.
• Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, Smith PJ, Beall BW, Whitney CG, Moore MR; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010 Jan 1;201(1):32-41. doi: 10.1086/648593.
• Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, Tyrrell GJ, Desai S, Sherrard L, Adam H, Gilmour M, Zhanel GG; Toronto Bacterial Diseases Network; Canadian Public Health Laboratory Network. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012. Can J Microbiol. 2013 Dec;59(12):778-88. doi: 10.1139/cjm-2013-0614. Epub 2013 Oct 21.
• Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015 May;15(5):535-43. doi: 10.1016/S1473-3099(15)70044-7. Epub 2015 Mar 20.
• van der Linden M, Falkenhorst G, Perniciaro S, Imohl M. Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany. PLoS One. 2015 Jul 1;10(7):e0131494. doi: 10.1371/journal.pone.0131494. eCollection 2015.
• Self WH, Wunderink RG, Williams DJ, Barrett TW, Baughman AH, Grijalva CG. Comparison of clinical prediction models for resistant bacteria in community-onset pneumonia. Acad Emerg Med. 2015 Jun;22(6):730-40. doi: 10.1111/acem.12672. Epub 2015 May 20.
• Grijalva CG, Wunderink RG, Zhu Y, Williams DJ, Balk R, Fakhran S, Courtney DM, Anderson EJ, Qi C, Trabue C, Pavia AT, Moore MR, Jain S, Edwards KM, Self WH. In-Hospital Pneumococcal Polysaccharide Vaccination Is Associated With Detection of Pneumococcal Vaccine Serotypes in Adults Hospitalized for Community-Acquired Pneumonia. Open Forum Infect Dis. 2015 Sep 19;2(4):ofv135. doi: 10.1093/ofid/ofv135. eCollection 2015 Dec.
• Upchurch CP, Grijalva CG, Wunderink RG, Williams DJ, Waterer GW, Anderson EJ, Zhu Y, Hart EM, Carroll F, Bramley AM, Jain S, Edwards KM, Self WH. Community-Acquired Pneumonia Visualized on CT Scans but Not Chest Radiographs: Pathogens, Severity, and Clinical Outcomes. Chest. 2018 Mar;153(3):601-610. doi: 10.1016/j.chest.2017.07.035. Epub 2017 Aug 9.
• Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003 May;58(5):377-82. doi: 10.1136/thorax.58.5.377.
• Collin C, Wade DT, Davies S, Horne V. The Barthel ADL Index: a reliability study. Int Disabil Stud. 1988;10(2):61-3. doi: 10.3109/09638288809164103.
• Colantuoni E, Scharfstein DO, Wang C, Hashem MD, Leroux A, Needham DM, Girard TD. Statistical methods to compare functional outcomes in randomized controlled trials with high mortality. BMJ. 2018 Jan 3;360:j5748. doi: 10.1136/bmj.j5748.
• EuroQol. EQ-5D-5L Valuation, Crosswalk Index Value Calculator. Available at: https://euroqol.org/eq-5d- instruments/eq-5d-5l-about/valuation/crosswalk-index-valuecalculator/ Accessed 25 May 2018.
• Dowdy DW, Eid MP, Sedrakyan A, Mendez-Tellez PA, Pronovost PJ, Herridge MS, Needham DM. Quality of life in adult survivors of critical illness: a systematic review of the literature. Intensive Care Med. 2005 May;31(5):611-20. doi: 10.1007/s00134-005-2592-6. Epub 2005 Apr 1.
• Dorman PJ, Slattery J, Farrell B, Dennis MS, Sandercock PA. A randomised comparison of the EuroQol and Short Form-36 after stroke. United Kingdom collaborators in the International Stroke Trial. BMJ. 1997 Aug 23;315(7106):461. doi: 10.1136/bmj.315.7106.461. No abstract available.
• Angus DC, Carlet J; 2002 Brussels Roundtable Participants. Surviving intensive care: a report from the 2002 Brussels Roundtable. Intensive Care Med. 2003 Mar;29(3):368-77. doi: 10.1007/s00134-002-1624-8. Epub 2003 Jan 21.
• Self WH, Grijalva CG, Zhu Y, Talbot HK, Jules A, Widmer KE, Edwards KM, Williams JV, Shay DK, Griffin MR. Emergency department visits for influenza A(H1N1)pdm09, Davidson County, Tennessee, USA. Emerg Infect Dis. 2012 May;18(5):863-5. doi: 10.3201/eid1805.111233.
• Tchetgen Tchetgen EJ. Identification and estimation of survivor average causal effects. Stat Med. 2014 Sep 20;33(21):3601-28. doi: 10.1002/sim.6181. Epub 2014 May 29.

Study record dates

Study Major Dates

• Study Start (Actual): June 28, 2022
• Primary Completion (Actual): February 25, 2025
• Study Completion (Actual): February 25, 2025

Study Registration Dates

• First Submitted: November 27, 2025
• First Submitted That Met QC Criteria: January 14, 2026
• First Posted (Actual): January 21, 2026

Study Record Updates

• Last Update Posted (Actual): January 21, 2026
• Last Update Submitted That Met QC Criteria: January 14, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: CAP; Community Acquired Pneumonia; Colombia; Pneumococcal Pneumonia; Pneumo-CAP
• Additional Relevant MeSH Terms: Respiratory Tract Infections; Infections; Respiratory Tract Diseases; Lung Diseases; Pneumonia; Gram-Positive Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Streptococcal Infections; Pneumococcal Infections; Pneumonia, Bacterial; Community-Acquired Infections; Pneumonia, Pneumococcal; Community-Acquired Pneumonia
• Other Study ID Numbers: MED-357-2023

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: The decision regarding the sharing of individual participant data has not yet been finalized. IPD availability will depend on ethical approvals, institutional policies, and data-governance requirements across participating sites.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No